Natural history and clinical features of aspirin-exacerbated respiratory disease

被引:0
|
作者
John M. Fahrenholz
机构
关键词
Aspirin-sensitive asthma; aspirin triad; nonsteroidal antiinflammatory drugs; adverse reactions;
D O I
暂无
中图分类号
学科分类号
摘要
Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by chronic rhinosinusitis, nasal polyposis, asthma and precipitation of asthma, and rhinitis attacks after ingestion of aspirin (ASA) and most other nonsteroidal antiinflammatory drugs (NSAIDs). Although precipitation of asthma attacks by ingestion of ASA and other NSAIDs is considered a hallmark of the syndrome, the respiratory mucosal inflammatory disease process begins and continues in the absence of ongoing or even intermittent exposure to ASA or NSAIDs. The typical patient with AERD is an adult who develops refractory chronic rhinitis in the third or fourth decade of life. The chronic rhinitis evolves into chronic eosinophilic rhinosinusitis with associated nasal polyposis. Anosmia appears in most patients. CT of the sinuses most often demonstrates pansinusitis and patients often undergo multiple sinus operations resulting in only limited temporary benefit. During the evolution of the sinus disease persistent asthma develops. Finally, if patients are exposed to ASA or NSAIDs acute respiratory reactions begin to occur. Despite subsequent avoidance of ASA and other NSAIDs, the respiratory mucosal inflammatory disease persists, often requiring systemic corticosteroids for control of both upper- and lower-respiratory tract symptoms. Adequate control of asthma can often only be accomplished with the simultaneous control of the associated rhinosinusitis. With few exceptions, once AERD develops it remains for the remainder of the patient’s life.
引用
收藏
页码:113 / 124
页数:11
相关论文
共 50 条
  • [21] Aspirin-exacerbated respiratory disease: A review
    Dominas, Christine
    Gadkaree, Shekhar
    Maxfield, Alice Z.
    Gray, Stacey T.
    Bergmark, Regan W.
    LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2020, 5 (03): : 360 - 367
  • [22] Aspirin-exacerbated respiratory disease: an update
    Duy Le Pham
    Lee, Ji-Ho
    Park, Hae-Sim
    CURRENT OPINION IN PULMONARY MEDICINE, 2017, 23 (01) : 89 - 96
  • [23] Update on Aspirin-Exacerbated Respiratory Disease
    Katharine M. Woessner
    Current Allergy and Asthma Reports, 2017, 17
  • [24] Pathogenesis of aspirin-exacerbated respiratory disease
    Stevenson, DD
    Zuraw, BL
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2003, 24 (02) : 169 - 187
  • [25] Aspirin-exacerbated respiratory disease: Burden of disease
    Chang, Jinny E.
    White, Andrew
    Simon, Ronald A.
    Stevenson, Donald D.
    ALLERGY AND ASTHMA PROCEEDINGS, 2012, 33 (02) : 117 - 121
  • [26] The clinical dilemma of "silent desensitization" in aspirin-exacerbated respiratory disease
    White, Andrew A.
    Bosso, John V.
    Stevenson, Donald D.
    ALLERGY AND ASTHMA PROCEEDINGS, 2013, 34 (04) : 378 - 382
  • [27] INVESTIGATING THE CLINICAL AND MOLECULAR ASPECTS OF ASPIRIN-EXACERBATED RESPIRATORY DISEASE
    Stevens, W.
    Ocampo, C.
    Sakashita, M.
    Mahdavinia, M.
    Peters, A.
    Avila, P.
    Kern, R.
    Schleimer, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (05) : A29 - A29
  • [28] Performing Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease
    Waldram, Jeremy D.
    Simon, Ronald A.
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2016, 36 (04) : 693 - +
  • [29] Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances
    Steinke, John W.
    Wilson, Jeff M.
    JOURNAL OF ASTHMA AND ALLERGY, 2016, 9 : 37 - 43
  • [30] Aspirin-exacerbated respiratory disease: aspirin desensitisation treatment
    Geraldo Dias, J.
    Costa, A.
    Caiado, J.
    Pedro, E.
    Pereira Barbosa, M.
    ALLERGY, 2010, 65 : 603 - 604